Tadalafil as monotherapy and in combination regimens for the treatment of pulmonary arterial hypertension

Tadalafil as monotherapy and in combination regimens for the treatment of pulmonary arterial hypertension

The purpose of this review is to evaluate the use of tadalafil as monotherapy and in combination regimens for the treatment of pulmonary arterial hypertension (PAH). A systematic English language search of the medical literature using PubMed was conducted between January 1960 and May 2012 using the...

Full description

Bibliographic Details
Main Authors:	Dioma U. Udeoji, Ernst R. Schwarz
Format:	Article
Language:	English
Published:	SAGE Publishing 2013-02-01
Series:	Therapeutic Advances in Respiratory Disease
Online Access:	https://doi.org/10.1177/1753465812463627

Similar Items

Switching from Nitrate Therapy to Ranolazine in Patients with Coronary Artery Disease Receiving Phosphodiesterase Type-5 Inhibitors for Erectile Dysfunction
by: Dioma U. Udeoji, et al.
Published: (2014-11-01)

Switching from Nitrate Therapy to Ranolazine in Patients with Coronary Artery Disease Receiving Phosphodiesterase Type-5 Inhibitors for Erectile Dysfunction
by: Dioma U. Udeoji, et al.
Published: (2014-01-01)

The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension
by: Jeremy A Falk, et al.
Published: (2010-04-01)

Effects of macitentan and tadalafil monotherapy or their combination on the right ventricle and plasma metabolites in pulmonary hypertensive rats
by: Argen Mamazhakypov, et al.
Published: (2020-11-01)

Tadalafil para o tratamento da hipertensão arterial pulmonar idiopática Tadalafil as treatment for idiopathic pulmonary arterial hypertension
by: Adriana Castro de Carvalho, et al.
Published: (2006-11-01)

Sibutramine monotherapy in arterial hypertension combined with obesity
by: S. V. Nedogoda, et al.
Published: (2009-08-01)

Combined use of arginase II inhibitors and tadalafil for the correction of monocrotaline pulmonary hypertension
by: Ivan S. Koklin, et al.
Published: (2019-09-01)

Tadalafil Nanoemulsion Mists for Treatment of Pediatric Pulmonary Hypertension via Nebulization
by: Bassant Elbardisy, et al.
Published: (2022-12-01)

P161 Successful treatment of pulmonary hypertension and grade 3 lupus nephritis with triple combination treatment for pulmonary hypertension (Macitentan, Tadalafil, Selexipag) and cyclophosphamide
by: Azeem Ahmed, et al.
Published: (2024-03-01)

Profiles and treatment patterns of patients with pulmonary arterial hypertension on monotherapy at experienced centres
by: Max Wissmüller, et al.
Published: (2022-10-01)

Monotherapy in patients with pulmonary arterial hypertension at four German PH centres
by: Beate Stubbe, et al.
Published: (2021-04-01)

Safety, tolerability, and efficacy of an in‐class combination therapy switch from bosentan plus sildenafil to ambrisentan plus tadalafil in children with pulmonary arterial hypertension
by: Cara Morgan, et al.
Published: (2024-10-01)

Addition of Sildenafil in Patients with Pulmonary Arterial Hypertension with Inadequate Response to Bosentan Monotherapy
by: Nancy R Porhownik, et al.
Published: (2008-01-01)

A randomized clinical trial to evaluate efficacy and safety of monotherapy with tadalafil or tamsulosin and their combination in men with benign prostatic hyperplasia
by: M. Bibi, et al.
Published: (2020-07-01)

Combination therapy for the treatment of pulmonary arterial hypertension
by: Andrew T. Levinson, et al.
Published: (2011-12-01)

Monotherapy versus combination therapy for the initial treatment of hypertension
by: Simardeep Kaur Shina
Published: (2020-01-01)

Tadalafil, a Long-Acting Inhibitor of PDE5, Improves Pulmonary Hemodynamics and Survival Rate of Monocrotaline-Induced Pulmonary Artery Hypertension in Rats
by: Fusae Sawamura, et al.
Published: (2009-01-01)

EFFECTS OF TADALAFIL ON CARDIOPULMONARY HAEMODYNAMICS IN PATIENTS OF CHRONIC PULMONARY DISEASES WITH PULMONARY HYPERTENSION: A PILOT STUDY
by: Indrajeet Sharma, et al.
Published: (2016-03-01)

The impact of ambrisentan and tadalafil upfront combination therapy on cardiac function in scleroderma associated pulmonary arterial hypertension patients: cardiac magnetic resonance feature tracking study
by: Takahiro Sato, et al.
Published: (2018-02-01)

Comparing monotherapy with tadalafil or tamsulosin in men with benign prostatic hyperplasia: A case–control study
by: Hayder Adnan Fawzi, et al.
Published: (2024-07-01)

Efficacy and safety of combination treatment with tadalafil and mirabegron for persistent storage symptoms despite tadalafil treatment in patients with benign prostatic hyperplasia
by: M. Honda, et al.
Published: (2020-07-01)

Tadalafil for veterans with chronic obstructive pulmonary disease—pulmonary hypertension: A multicenter, placebo‐controlled randomized trial
by: Bradley A. Maron, et al.
Published: (2022-01-01)

Efficacy and safety of tadalafil in a pediatric population with pulmonary arterial hypertension: phase 3 randomized, double-blind placebo-controlled study
by: Dunbar Ivy, et al.
Published: (2021-06-01)

The Daily Therapy With L-Arginine 2,500 mg and Tadalafil 5 mg in Combination and in Monotherapy for the Treatment of Erectile Dysfunction: A Prospective, Randomized Multicentre Study
by: Luigi Gallo, MD, et al.
Published: (2020-06-01)

Tadalafil in the treatment of erectile dysfunction
by: Robert M Coward, et al.
Published: (2008-12-01)

The role of tadalafil in treated hypertensive patients with erectile dysfunction
by: Ehud Grossman
Published: (2022-02-01)

Assessing the Efficacy of Tadalafil in Reducing Pulmonary Hypertension in Children and Adolescents Aged 5 Months-15 Years
by: MR Alipour, et al.
Published: (2015-11-01)

Successful treatment of pulmonary hypertension following hematopoietic stem cell transplant with a single oral tadalafil: a case report
by: Toshikazu D. Tanaka, et al.
Published: (2021-06-01)

RENAISSANCE OF ARTERIAL HYPERTENSION MONOTHERAPY – THE POSITION OF THIAZIDE DIURETICS
by: T. V. Adasheva, et al.
Published: (2012-10-01)

Twelve-Year Survival in a Patient With Systemic Sclerosis–Associated Pulmonary Arterial Hypertension on Nifedipine Monotherapy
by: Scott A. Helgeson, MD, et al.
Published: (2019-09-01)

Combination therapy is a new standard for treatment of pulmonary arterial hypertension
by: S N Avdeev, et al.
Published: (2018-03-01)

Multicenter review of a tadalafil suspension formulation for infants and children with pulmonary hypertension: A North American experience
by: David Edward Youssef, et al.
Published: (2023-01-01)

Tadalafil-loaded PLGA microspheres for pulmonary administration: preparation and evaluation
by: Zhenlei Yang, et al.
Published: (2019-12-01)

Efficacy of a combination of dutasteride, tadalafil, and solifenacin in the treatment of previously unsuccessful patients
by: Kirill Kosilov, et al.
Published: (2022-01-01)

Ambrisentan for the treatment of pulmonary arterial hypertension
by: Brian Casserly, et al.
Published: (2008-12-01)

Cost-effectiveness analysis of selexipag for the combined treatment of pulmonary arterial hypertension
by: Wenxing Dong, et al.
Published: (2023-08-01)

CLINICAL EFFECTS AND RENOPROTECTIVE FACILITIES OF OLMESARTAN AND LERKANIDIPINEAS MONOTHERAPY AND WHEN COMBINED APPLICATION IN PATIENTS WITH ARTERIAL HYPERTENSION
by: A G Evdokimova, et al.
Published: (2016-03-01)

Treatment of community-onset pneumonia in neutropenic cancer patients: β-lactam monotherapy versus combination antibiotic regimens
by: Hyeri Seok, et al.
Published: (2019-06-01)

THE EFFECTIVENESS OF COMBINATION THERAPY WITH BOSENTAN AND SILDENAFIL IN PATIENTS WITH THE CLINICAL WORSENING OF IDIOPATHIC PULMONARY HYPERTENSION ON THE BACKGROUND OF SPECIFIC MONOTHERAPY
by: V. M. Paramonov, et al.
Published: (2016-12-01)

Pulmonary Arterial Hypertension Specific Therapy in Patients with Combined Post- and Precapillary Pulmonary Hypertension
by: Hassan Alfraidi, et al.
Published: (2018-01-01)